Human evidence record · Selank
Selank plus phenazepam versus phenazepam monotherapy in anxiety disorders
The combination arm was reported to improve aspects of anxiolytic treatment and tolerability.
Quick read
Human evidence record
What this study tells us
This study compared groups, which is more informative than an uncontrolled report. The amount of confidence still depends on how the groups were formed, how outcomes were measured and how well bias was controlled.
Who was studied?
Patients with anxiety-phobic, hypochondriac and somatoform disorders
How many?
n=70
What happened?
The combination arm was reported to improve aspects of anxiolytic treatment and tolerability.
What stops us overclaiming?
Adjunct design cannot isolate Selank's independent effect; older regional evidence.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
The combination arm was reported to improve aspects of anxiolytic treatment and tolerability.
Study details
Study designComparative adjunct-treatment clinical study
PopulationPatients with anxiety-phobic, hypochondriac and somatoform disorders
Sample size70
RouteClinical Selank formulation
Regimen / exposurePhenazepam monotherapy n=30 versus Selank + phenazepam n=40
DurationClinical treatment course
ComparatorPhenazepam monotherapy
Primary endpoint / questionAnxiety, depression, CGI, Spielberger scales and tolerability
Safety resultNo large modern pharmacovigilance framework was established.
Key limitationsAdjunct design cannot isolate Selank's independent effect; older regional evidence.
Registry / identifierPMID 26356395